Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ESRRA | P11474 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501202 | 0.87 | ATM (0.50) | ATMSMN1; SMN2ALOX5LMNAALDH1A1 | |
| SCHEMBL6506790 | 0.80 | ALOX5 (0.52) | ATMSMN1; SMN2ALOX5LMNAALDH1A1 | |
| SCHEMBL242325 | 0.78 | ATM (0.57) | ATMSMN1; SMN2ALOX5LMNAALDH1A1 | |
| SCHEMBL6499714 | 0.77 | ALOX5 (0.51) | ATMSMN1; SMN2ALOX5LMNAALDH1A1 | |
| SCHEMBL6501171 | 0.77 | ATM (0.56) | ATMSMN1; SMN2ALOX5LMNAALDH1A1 | |
| SCHEMBL6507010 | 0.76 | ALOX5 (0.50) | ATMSMN1; SMN2ALOX5LMNAALDH1A1 | |
| SCHEMBL6507440 | 0.75 | ATM (0.57) | ATMSMN1; SMN2ALOX5LMNAALDH1A1 | |
| SCHEMBL6499063 | 0.74 | ALOX5 (0.50) | ATMSMN1; SMN2ALOX5LMNAALDH1A1 | |
| SCHEMBL2823924 | 0.74 | ATM (0.55) | ATMSMN1; SMN2ALOX5LMNAALDH1A1 | |
| SCHEMBL8698430 | 0.74 | KMO (0.63) | ATMSMN1; SMN2ALOX5LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | disclosed |
| EP-1229024-A1 | m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRIN ALPHA-V BETA-3 ANTAGONISM | MEIJI SEIKA KAISHA LTD. (JP) | 2002-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | ITGAV, ITGB3, ITGA4 | ATM 4449/4885SMN1; SMN2 1363/4885ALOX5 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.